Tracey Taylor
Acute Care · Milton, FLNPI 1437519618
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 267 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AstraZeneca at 29.4% of the total. 2025 is the largest year on record at $1,748, 2.3 times the $754 reported in 2021. Among acute care clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 267 payments — averaging $18.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$1K
- Boehringer Ingelheim$553
- Regeneron Healthcare Solutions, Inc.$313
- Amgen$258
- Insmed, Inc.$251
- plus $950 from 14 others
What the payments were for
- Food & beverage$4,956100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 55 | $1,458 |
| GSK | 91 | $1,173 |
| Boehringer Ingelheim | 31 | $553 |
| Regeneron Healthcare Solutions, Inc. | 17 | $313 |
| Amgen | 18 | $258 |
| Insmed, Inc. | 10 | $251 |
| Verona Pharma, Inc. | 10 | $210 |
| Sanofi | 9 | $209 |
| Avadel CNS Pharmaceuticals, LLC | 5 | $136 |
| Philips North America LLC | 6 | $106 |
| Inspire Medical Systems, Inc. | 4 | $102 |
| Jazz Pharmaceuticals Inc. | 2 | $45 |
| Mylan Specialty L.p. | 1 | $23 |
| Inogen, Inc. | 2 | $20 |
| Merck | 1 | $20 |
| Abbott | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $15 |
| 3b Medical, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,956 in reported general payments places this provider in the 95th percentile of 1,150 acute care providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 522 | $460,483 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 175 | $145,391 |
| Breo ElliptaFluticasone/Vilanterol | 184 | $90,535 |
| TezspireTezepelumab-Ekko | 18 | $79,276 |
| SymbicortBudesonide/Formoterol Fumarate | 196 | $74,876 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 96 | $63,948 |
| Spiriva RespimatTiotropium Bromide | 37 | $43,960 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 49 | $43,341 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 1,042 | $32,700 |
| Advair HfaFluticasone Propion/Salmeterol | 55 | $25,548 |
| Spiriva HandihalerTiotropium Bromide | 15 | $17,854 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 28 | $14,977 |
| Incruse ElliptaUmeclidinium Bromide | 19 | $11,392 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 79 | $10,866 |
| Ventolin HfaAlbuterol Sulfate | 115 | $8,188 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,173 | $605,751774 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $1,458 | $299,543389 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $553 | $122,886161 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,150 acute care providers in Florida.
Other acute care in Milton
- Melisa WilsonOrlando$214K
- Amanda PeacockJacksonville$81K
- Katrina RileyTampa$66K
- Diane GrayLake Mary$49K
- Heather RamousSafety Harbor$38K
- Melanie WeresJacksonville$37K
- Jayne JaramilloJacksonville$27K
- Melissa HamiltonTampa$23K
- Kimberly GrantAltamonte Springs$20K
- Julie ElliottWinter Haven$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.